<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD10240000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P08758</UniProt_ID>
  <Seq_Length>320</Seq_Length>
  <Molecule_Weight>35937</Molecule_Weight>
  <KEGG_ID>hsa:308</KEGG_ID>
  <Orthology_ID>K16646</Orthology_ID>
  <Function_Summary>This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade.</Function_Summary>
  <Pfam_ID>PF00191:Annexin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>2</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Annexin-5</Alias>
      <Alias>Annexin V</Alias>
      <Alias>PAP-I</Alias>
      <Alias>Endonexin II</Alias>
      <Alias>Anchorin CII</Alias>
      <Alias>Lipocortin V</Alias>
      <Alias>Placental anticoagulant protein 4</Alias>
      <Alias>Vascular anticoagulant-alpha</Alias>
      <Alias>Calphobindin I</Alias>
      <Alias>CBP-I</Alias>
      <Alias>Placental anticoagulant protein I</Alias>
      <Alias>Thromboplastin inhibitor</Alias>
      <Alias>VAC-alpha</Alias>
      <Alias>PP4</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any component on the surface of a eukaryotic cell.</Detail>
      <Keyword>Eukaryotic cell surface binding</Keyword>
      <Ontology_ID>GO:0043499</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with phospholipids, a class of lipids containing phosphoric acid as a mono- or diester, in the presence of calcium.</Detail>
      <Keyword>Calcium-dependent phospholipid binding</Keyword>
      <Ontology_ID>GO:0005544</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Stops, prevents or reduces the activity of a phospholipase, an enzyme that catalyzes of the hydrolysis of a phospholipid.</Detail>
      <Keyword>Phospholipase inhibitor activity</Keyword>
      <Ontology_ID>GO:0004859</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with calcium ions (Ca2+).</Detail>
      <Keyword>Calcium ion binding</Keyword>
      <Ontology_ID>GO:0005509</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organic substance stimulus.</Detail>
      <Keyword>Response to organic substance</Keyword>
      <Ontology_ID>GO:0010033</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.</Detail>
      <Keyword>Hemostasis</Keyword>
      <Ontology_ID>GO:0007599</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of coagulation.</Detail>
      <Keyword>Negative regulation of coagulation</Keyword>
      <Ontology_ID>GO:0050819</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal, e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light, and ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell, and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.</Detail>
      <Keyword>Signal transduction</Keyword>
      <Ontology_ID>GO:0007165</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>76</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>70</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>97</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>79</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>2</Position>
      <PTM_Type>N-acetylalanine</PTM_Type>
    </PTM>
    <PTM>
      <Position>101</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MAQVLRGTVTDFPGFDERADAETLRKAMKGLGTDEESILTLLTSRSNAQRQEISAAFKTLFGRDLLDDLKSELTGKFEKLIVALMKPSRLYDAYELKHALKGAGTNEKVLTEIIASRTPEELRAIKQVYEEEYGSSLEDDVVGDTSGYYQRMLVVLLQANRDPDAGIDEAQVEQDAQALFQAGELKWGTDEEKFITIFGTRSVSHLRKVFDKYMTISGFQIEETIDRETSGNLEQLLLAVVKSIRSIPAYLAETLYYAMKGAGTDDHTLIRVMVSRSEIDLFNIRKEFRKNFATSLYSMIKGDTSGDYKKALLLLCGEDD</Protein_Seq>
    <DNA_Seq>GTTGCTTGGATCAGTCTAGGTGCAGCTGCCGGATCCTTCAGCGTCTGCATCTCGGCGTCGCCCCGCGTACCGTCGCCCGGCTCTCCGCCGCTCTCCCGGGGTTTCGGGGCACTTGGGTCCCACAGTCTGGTCCTGCTTCACCTTCCCCTGACCTGAGTAGTCGCCATGGCACAGGTTCTCAGAGGCACTGTGACTGACTTCCCTGGATTTGATGAGCGGGCTGATGCAGAAACTCTTCGGAAGGCTATGAAAGGCTTGGGCACAGATGAGGAGAGCATCCTGACTCTGTTGACATCCCGAAGTAATGCTCAGCGCCAGGAAATCTCTGCAGCTTTTAAGACTCTGTTTGGCAGGGATCTTCTGGATGACCTGAAATCAGAACTAACTGGAAAATTTGAAAAATTAATTGTGGCTCTGATGAAACCCTCTCGGCTTTATGATGCTTATGAACTGAAACATGCCTTGAAGGGAGCTGGAACAAATGAAAAAGTACTGACAGAAATTATTGCTTCAAGGACACCTGAAGAACTGAGAGCCATCAAACAAGTTTATGAAGAAGAATATGGCTCAAGCCTGGAAGATGACGTGGTGGGGGACACTTCAGGGTACTACCAGCGGATGTTGGTGGTTCTCCTTCAGGCTAACAGAGACCCTGATGCTGGAATTGATGAAGCTCAAGTTGAACAAGATGCTCAGGCTTTATTTCAGGCTGGAGAACTTAAATGGGGGACAGATGAAGAAAAGTTTATCACCATCTTTGGAACACGAAGTGTGTCTCATTTGAGAAAGGTGTTTGACAAGTACATGACTATATCAGGATTTCAAATTGAGGAAACCATTGACCGCGAGACTTCTGGCAATTTAGAGCAACTACTCCTTGCTGTTGTGAAATCTATTCGAAGTATACCTGCCTACCTTGCAGAGACCCTCTATTATGCTATGAAGGGAGCTGGGACAGATGATCATACCCTCATCAGAGTCATGGTTTCCAGGAGTGAGATTGATCTGTTTAACATCAGGAAGGAGTTTAGGAAGAATTTTGCCACCTCTCTTTATTCCATGATTAAGGGAGATACATCTGGGGACTATAAGAAAGCTCTTCTGCTGCTCTGTGGAGAAGATGACTAACGTGTCACGGGGAAGAGCTCCCTGCTGTGTGCCTGCACCACCCCACTGCCTTCCTTCAGCACCTTTAGCTGCATTTGTATGCCAGTGCTTAACACATTGCCTTATTCATACTAGCATGCTCATGACCAACACATACACGTCATAGAAGAAAATAGTGGTGCTTCTTTCTGATCTCTAGTGGAGATCTCTTTGACTGCTGTAGTACTAAAGTGTACTTAATGTTACTAAGTTTAATGCCTGGCCATTTTCCATTTATATATATTTTTTAAGAGGCTAGAGTGCTTTTAGCCTTTTTTAAAAACTCCATTTATATTACATTTGTAACCATGATACTTTAATCAGAAGCTTAGCCTTGAAATTGTGAACTCTTGGAAATGTTATTAGTGAAGTTCGCAACTAAACTAAACCTGTAAAATTATGATGATTGTATTCAAAAGATTAATGAAAAATAAACATTTCTGTCCCCCTGAAAAAAAAAAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endothelial microparticle</CellLocal>
      <Ontology_ID>GO:0072563</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular vesicular exosome</CellLocal>
      <Ontology_ID>GO:0070062</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>External side of plasma membrane</CellLocal>
      <Ontology_ID>GO:0009897</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>ANXA5</Gene_Name>
    <Gene_Alias>ANX5; ENX2; PP4</Gene_Alias>
    <Gene_ID>308</Gene_ID>
    <Genbank_ACCN>NM_001154</Genbank_ACCN>
    <Protein_ACCN>NP_001145</Protein_ACCN>
    <HGNC_ID>543</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/308</Gene_URL>
    <UCSC_ID>uc003idu.4</UCSC_ID>
    <EMBL_ID>ENSG00000164111</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Pregnancy Loss, Recurrent 3</Disease_Name>
      <Disease_Detail>Pregnancy Loss</Disease_Detail>
      <Disease_DB>PRG093</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pregnancy_loss_recurrent_3?search=ANXA5#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Transposition of the Great Arteries</Disease_Name>
      <Disease_Detail>Transposition of the Great Arteries</Disease_Detail>
      <Disease_DB>TRN044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/transposition_of_the_great_arteries?search=ANXA5#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Barth Syndrome</Disease_Name>
      <Disease_Detail>Barth Syndrome</Disease_Detail>
      <Disease_DB>BRT005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/barth_syndrome?search=ANXA5#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Amelanotic Melanoma</Disease_Name>
      <Disease_Detail>Amelanotic Melanoma</Disease_Detail>
      <Disease_DB>AML001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/amelanotic_melanoma?search=ANXA5#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pancreatic Cancer</Disease_Name>
      <Disease_Detail>Pancreatic Cancer</Disease_Detail>
      <Disease_DB>PNC035</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pancreatic_cancer?search=ANXA5#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pregnancy Loss</Disease_Name>
      <Disease_Detail>Pregnancy Loss</Disease_Detail>
      <Disease_DB>PRG060</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pregnancy_loss?search=ANXA5#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Multiple Endocrine Neoplasia Type 2a</Disease_Name>
      <Disease_Detail>Multiple Endocrine Neoplasia</Disease_Detail>
      <Disease_DB>MLT042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/multiple_endocrine_neoplasia_type_2a?search=ANXA5#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Antiphospholipid Syndrome</Disease_Name>
      <Disease_Detail>Antiphospholipid Syndrome</Disease_Detail>
      <Disease_DB>ANT006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/antiphospholipid_syndrome?search=ANXA5#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>THE EFFECT OF METAL BINDING ON THE STRUCTURE OF ANNEXIN V AND IMPLICATIONS FOR MEMBRANE BINDING</PDB_Title>
      <PDB_ID>1ANW</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ANW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The effect of metal binding on the structure of annexin V and implications for membrane binding.</PubMed_Title>
      <Author>Lewit-Bentley, A., et al.</Author>
      <Journal>Eur.J.Biochem.(1992)210:73-77</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1446685?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF RECOMBINANT HUMAN PLACENTAL ANNEXIN V COMPLEXED WITH K-201 AS A CALCIUM CHANNEL ACTIVITY INHIBITOR</PDB_Title>
      <PDB_ID>1HAK</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HAK</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10240001</ASD_Ligand>
      <PubMed_Title>Crystal structure of annexin V with its ligand K-201 as a calcium channel activity inhibitor.</PubMed_Title>
      <Author>Kaneko, N., et al.</Author>
      <Journal>J.Mol.Biol.(1997)274:16-20</Journal>
      <PubMed_ID>9398511</PubMed_ID>
    </PDB>
  </PDB_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.bbb.b.b.g.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha </CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1anw</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,79,Lys;site,267,His</Site_Detail>
      <Site_Reference>Agarwal R, et al. J Mol Biol. 2007 Apr 27;368(2):450-63.</Site_Reference>
      <PDB_ID>1ANX;1AVH;1AVR;1HAK;1HVF;1HVG;2XO2;2XO3</PDB_ID>
      <PubMed_ID>9378099</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD10240001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10248001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2013-04-23</Create_Date>
</Organism_Record>